Kalaris Therapeutics Inc(KLRS)

Biotechnology · Berkeley Heights, NJ

$2.81-0.02 (-0.71%)

Delayed quote: Oct 6, 2026, 12:27 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:33:00.633Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:33:00.633Z.

Quote observation: 2026-10-06T16:27:13.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -47,731,000
Quote market capitalization: 61,335,354
Total debt · period ending 2026-06-30: 1,400,000
Cash · period ending 2026-06-30: 43,173,000

FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KLRS EBITDA Yield Metrics

EBITDA YIELD

N/A

KLRS Competitors' EBITDA Yield

KLRS

Kalaris Therapeutics Inc

Current

Market Cap

$61.34M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTB

Connect Biopharma Holdings Limited

vs KLRS

Market Cap

$61.04M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs KLRS

Market Cap

$60.69M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs KLRS

Market Cap

$60.08M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs KLRS

Market Cap

$59.66M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs KLRS

Market Cap

$59.75M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs KLRS

Market Cap

$63.02M

EBITDA Yield

N/A

TTM Avg

13.59%

3Y Avg

8.25%

5Y Avg

8.86%

PLRX

Pliant Therapeutics, Inc.

vs KLRS

Market Cap

$63.78M

EBITDA Yield

N/A

TTM Avg

8.85%

3Y Avg

8.85%

5Y Avg

8.85%

GUTS

Fractyl Health, Inc.

vs KLRS

Market Cap

$58.57M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALPS

Alps Group Inc

vs KLRS

Market Cap

$63.23M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Kalaris Therapeutics Inc (KLRS)	$61.34M	N/A	N/A	N/A	N/A
Connect Biopharma Holdings Limited (CNTB)vs ›	$61.04M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.69M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$60.08M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$59.66M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$59.75M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	13.59%	8.25%	8.86%
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.78M	N/A	8.85%	8.85%	8.85%
Fractyl Health, Inc. (GUTS)vs ›	$58.57M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$63.23M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

KLRS EBITDA Yield Metrics

KLRS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics